Kolon Life Science Inc.

KOSDAQ:A102940 Stock Report

Market Cap: ₩239.7b

Kolon Life Science Past Earnings Performance

Past criteria checks 0/6

Kolon Life Science has been growing earnings at an average annual rate of 50.1%, while the Pharmaceuticals industry saw earnings growing at 10.1% annually. Revenues have been declining at an average rate of 1.9% per year.

Key information

50.1%

Earnings growth rate

50.1%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate-1.9%
Return on equity-19.2%
Net Margin-23.3%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Risks Still Elevated At These Prices As Kolon Life Science Inc. (KOSDAQ:102940) Shares Dive 26%

Mar 02
Risks Still Elevated At These Prices As Kolon Life Science Inc. (KOSDAQ:102940) Shares Dive 26%

We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt

Mar 12
We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt

A Look At Kolon Life Science's (KOSDAQ:102940) Share Price Returns

Jan 18
A Look At Kolon Life Science's (KOSDAQ:102940) Share Price Returns

Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt

Nov 26
Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt

Revenue & Expenses Breakdown

How Kolon Life Science makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A102940 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24131,823-30,72419,91514,982
31 Dec 23124,639-33,59920,22714,892
30 Sep 23130,353-19,77420,03913,542
30 Jun 23141,227-11,86919,98712,914
31 Mar 23164,138-85919,94214,206
31 Dec 22161,5844,01619,58113,583
30 Sep 22166,885-4,82817,19614,707
30 Jun 22167,707-4,94017,13614,653
31 Mar 22155,075-3,69317,17013,550
31 Dec 21165,485-1,37517,32014,327
30 Sep 21135,045-31,62720,06213,804
30 Jun 21134,850-29,15421,73914,032
31 Mar 21131,508-40,48525,03013,634
31 Dec 20129,413-43,19527,88813,154
31 Dec 19148,541-92,32330,45218,490
30 Sep 13139,92118,05615,17611,672
30 Jun 13141,62620,83714,80411,219

Quality Earnings: A102940 is currently unprofitable.

Growing Profit Margin: A102940 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A102940 is unprofitable, but has reduced losses over the past 5 years at a rate of 50.1% per year.

Accelerating Growth: Unable to compare A102940's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A102940 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.9%).


Return on Equity

High ROE: A102940 has a negative Return on Equity (-19.24%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.